Annovis Announces $6 Million Registered Direct Offering of Common Stock
Annovis (NYSE: ANVS) entered into definitive agreements to sell an aggregate of 4,000,000 shares of common stock (or pre-funded warrants) at $1.50 per share in a registered direct offering, with expected gross proceeds of approximately $6 million. Closing is expected on or about October 13, 2025, subject to customary conditions. H.C. Wainwright & Co. is the exclusive placement agent. The company intends to use net proceeds for working capital and general corporate purposes. The offering is being made under a shelf registration (Form S-3, Reg. No. 333-276814) with a prospectus supplement to be filed with the SEC.
Annovis (NYSE: ANVS) ha stipulato accordi definitivi per vendere un totale di 4,000,000 azioni ordinarie (o warrant prefinanziati) a $1.50 per azione in un'offerta diretta registrata, con proventi lordi previsti di circa $6 million. La chiusura è prevista per o intorno al 13 ottobre 2025, soggetta alle condizioni consuete. H.C. Wainwright & Co. è l'esclusivo agente di collocamento. L'azienda intende utilizzare i proventi netti per capitale circolante e scopi generali aziendali. L'offerta è effettuata nell'ambito di una registrazione shelf (Form S-3, Reg. No. 333-276814) con un supplemento di prospetto da depositare presso la SEC.
Annovis (NYSE: ANVS) ha celebrado acuerdos definitivos para vender un total de 4,000,000 acciones ordinarias (o warrants prefinanciados) a $1.50 por acción en una oferta directa registrada, con ingresos brutos esperados de aproximadamente $6 million. El cierre se espera alrededor del 13 de octubre de 2025, sujeto a condiciones habituales. H.C. Wainwright & Co. es el agente exclusivo de colocación. La empresa tiene la intención de usar los ingresos netos para capital de trabajo y fines corporativos generales. La oferta se realiza bajo un registro de estante (Form S-3, Reg. No. 333-276814) con un suplemento de prospecto que se presentará ante la SEC.
Annovis (NYSE: ANVS)는 등록된 직접 공모로 주당 $1.50에 4,000,000주의 보통주(또는 선충전 워런트)를 총 4,000,000주 판매하기로 하는 확정 계약에 서명했습니다. 예상 총수익은 약 $6 million입니다. 마감은 관례에 따른 조건의 충족 여부에 따라 2025년 10월 13일경으로 예상됩니다. H.C. Wainwright & Co.가 독점 배정 에이전트입니다. 회사는 순수익을 운전자본 및 일반 기업 목적에 사용할 예정입니다. 이 공모는Shelf 등록(Form S-3, Reg. No. 333-276814) 하에 이뤄지며 SEC에 제출될 Prospectus 보충서가 있습니다.
Annovis (NYSE: ANVS) a conclu des accords définitifs visant à vendre un total de 4,000,000 actions ordinaires (ou des warrants préfinancés) à $1.50 par action dans le cadre d'une offre directe enregistrée, avec des produits bruts attendus d'environ $6 millions. La clôture devrait avoir lieu vers le 13 octobre 2025, sous réserve des conditions habituelles. H.C. Wainwright & Co. est l'agent de placement exclusif. La société a l'intention d'utiliser les produits nets pour le fonds de roulement et des finalités générales d'entreprise. L'offre est réalisée dans le cadre d'une inscription sur étagère (Form S-3, Reg. No. 333-276814) avec un supplément de prospectus qui sera déposé auprès de la SEC.
Annovis (NYSE: ANVS) hat definitive Vereinbarungen getroffen, um insgesamt 4,000,000 Stammaktien (oder vorfinanzierte Warrants) zu einem Preis von $1.50 pro Aktie in einer registrierten Direktplatzierung zu verkaufen, wodurch Bruttoerlöse von ca. $6 Millionen erwartet werden. Der Abschluss wird voraussichtlich am oder rund zum 13. Oktober 2025 erfolgen, vorbehaltlich gängiger Bedingungen. H.C. Wainwright & Co. ist der exklusive Platzierungsagent. Das Unternehmen beabsichtigt, die Nettomittel für Betriebskapital und allgemeine Unternehmenszwecke zu verwenden. Das Angebot erfolgt im Rahmen einer Shelf-Registrierung (Form S-3, Reg. No. 333-276814) mit einem Prospektzusatz, der bei der SEC eingereicht wird.
Annovis (NYSE: ANVS) أبرمت اتفاقيات حاسمة لبيع إجمالي 4,000,000 سهم من الأسهم العادية (أو صكوك تمهيدية مُسبقة التمويل) بسعر $1.50 للسهم في عرض مباشر مسجل، مع توقع عوائد إجمالية تقارب $6 million. من المتوقع الإغلاق في أو نحو 13 أكتوبر 2025، رهناً بالشروط المعتادة. H.C. Wainwright & Co. هو وكيل الاكتتاب الحصري. الشركة تعتزم استخدام العوائد الصافية لرأس المال العامل ولأغراض الشركة العامة. يتم إجراء العرض بموجب تسجيل رفّ (Form S-3، Reg. No. 333-276814) مع مرفق نشرة عرض سيُقدم إلى هيئة الأوراق المالية الأمريكية (SEC).
Annovis (NYSE: ANVS) 已签署最终协议，拟以每股 $1.50 的价格通过注册直接发行方式出售总计 4,000,000 股普通股（或预先资助的认股权证），预计毛筹资额约为 $6 million。交割预计在大约 2025年10月13日 左右完成，需符合惯常条件。H.C. Wainwright & Co. 为独家配售代理。公司打算将净收益用于运营资金和一般企业用途。本次发行在一个托架注册(Form S-3, Reg. No. 333-276814)下进行，证券交易委员会将提交招股说明书补充文件至 SEC。
- Aggregate gross proceeds of approximately $6 million
- Definitive agreements executed for 4,000,000 shares at $1.50 per share
- Proceeds earmarked for working capital and general corporate purposes
- Offering conducted under an already effective Form S-3 shelf registration
- Issuance of 4,000,000 shares may cause notable shareholder dilution
- Placement agent fees and offering expenses will reduce net proceeds
- Closing is subject to customary conditions and may not occur on the expected Oct 13, 2025 date
Insights
Annovis secures ~
Annovis Bio agreed to sell 4,000,000 common shares (or pre-funded warrants) at
The cash infusion reduces near-term funding pressure but increases share count and potential dilution; placement agent fees and offering expenses will lower net proceeds. Key dependencies include successful closing on or about
Watch the filed prospectus supplement for precise fees, any use‑of‑proceeds breakdown, and whether pre-funded warrants convert. Near-term horizon: the next two weeks for closing and the next quarter for impact on cash runway.
MALVERN, Pa., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced that it has entered into definitive agreements for the purchase of an aggregate of 4,000,000 shares of its common stock (or pre-funded warrants in lieu thereof) at a purchase price of
H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
The aggregate gross proceeds to the Company from the offering are expected to be approximately
The securities described above are being offered and sold by the Company pursuant to a “shelf” registration statement on Form S-3 (Registration No. 333-276814), including a base prospectus, previously filed with the Securities and Exchange Commission (SEC) on February 1, 2024 and declared effective by the SEC on February 12, 2024. The offering is being made only by means of a prospectus supplement that forms a part of the registration statement. A prospectus supplement and an accompanying base prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov. Electronic copies of the prospectus supplement and accompanying base prospectus may also be obtained, when available, by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at (212) 856-5711 or e-mail at placements@hcwco.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
About Annovis
Headquartered in Malvern, Pennsylvania, Annovis is dedicated to addressing neurodegeneration in diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD). The Company is committed to developing innovative therapies that improve patient outcomes and quality of life. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.
Forward-Looking Statements
This press release contains forward-looking statements under the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended, including, without limitation, statements regarding the consummation of the offering, the satisfaction of closing conditions and the use of proceeds from the offering. Actual results may differ due to various risks and uncertainties, including those outlined in the Company’s SEC filings under “Risk Factors” in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update forward-looking statements except as required by law.
Contact Information:
Annovis Bio Inc.
101 Lindenwood Drive
Suite 225
Malvern, PA 19355
www.annovisbio.com
Investor Contact:
Alexander Morin, Ph.D.
Director, Strategic Communications
Annovis Bio
ir@annovisbio.com
FAQ
What is Annovis (ANVS) raising in the October 2025 registered direct offering?
When is the Annovis (ANVS) offering expected to close?
How does Annovis (ANVS) plan to use the net proceeds from the offering?
Who is the placement agent for Annovis (ANVS) registered direct offering?
Where can investors find the prospectus for the ANVS registered direct offering?
What immediate shareholder impacts should investors expect from the ANVS offering?
